AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+9.46%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$3.03B
AUM Growth
+$3.03B
(+3.1%)
Cap. Flow
+$76.1M
Cap. Flow
% of AUM
2.51%
Top 10 Holdings %
Top 10 Hldgs %
46.17%
Holding
153
New
22
Increased
19
Reduced
69
Closed
16
Top Buys
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$83M |
| 2 |
KLRS
Kalaris Therapeutics, Inc. Common Stock
KLRS
|
$63.9M |
| 3 |
KE Holdings
BEKE
|
$53.3M |
| 4 |
IGMS
IGM Biosciences
IGMS
|
$50.8M |
| 5 |
iTeos Therapeutics
ITOS
|
$27M |
Top Sells
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$42.9M |
| 2 |
PayPal
PYPL
|
$34.8M |
| 3 |
Avantor
AVTR
|
$34M |
| 4 |
argenx
ARGX
|
$33M |
| 5 |
Zillow
Z
|
$28.7M |
Sector Composition
| 1 | Healthcare | 78.37% |
| 2 | Consumer Discretionary | 13.95% |
| 3 | Technology | 3.4% |
| 4 | Real Estate | 1.76% |
| 5 | Materials | 1.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Atara Biotherapeutics
ATRA
$84.6M
| $29.2M | 0.71% | 2,250,000 -250,000 | -10% | -$3.24M |
|
|
ALBO
27
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $28.4M | 0.69% | 851,405 +351,045 | +70% | +$11.7M |
|
|
TPTX
28
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $28.4M | 0.69% | 325,000 -25,000 | -7% | -$2.18M |
|
29
uniQure
QURE
$896M
| $27.6M | 0.67% | 750,000 -250,000 | -25% | -$9.21M |
|
|
AGEN
30
Agenus
AGEN
$133M
| $27.6M | 0.67% | 6,900,000 +4,050,000 | +142% | +$16.2M |
|
|
31
iTeos Therapeutics
ITOS
| $27M | 0.66% | +1,094,047 | New | +$27M |
|
32
Taysha Gene Therapies
TSHA
$797M
| $25.6M | 0.62% | +1,140,882 | New | +$25.6M |
|
|
TRIL
33
DELISTED
Trillium Therapeutics Inc.
TRIL
| $21.3M | 0.52% | 1,500,000 +547,000 | +57% | +$7.77M |
|
34
Moderna
MRNA
$9.37B
| $21.2M | 0.52% | 300,000 -200,000 | -40% | -$14.2M |
|
35
StoneCo
STNE
$4.41B
| $21.2M | 0.51% | 400,000 +110,000 | +38% | +$5.82M |
|
|
36
Zillow
Z
$20.4B
| $20.3M | 0.49% | 200,000 -283,000 | -59% | -$28.7M |
|
|
TBIO
37
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $19.1M | 0.46% | 1,400,000 -200,000 | -13% | -$2.72M |
|
|
RUBY
38
DELISTED
Rubius Therapeutics, Inc
RUBY
| $18.9M | 0.46% | 3,778,913 -73,428 | -2% | -$368K |
|
39
Mersana Therapeutics
MRSN
$36.5M
| $18.6M | 0.45% | 1,000,000 +200,000 | +25% | +$3.72M |
|
40
Adverum Biotechnologies
ADVM
$64.6M
| $18.5M | 0.45% | 1,800,000 +900,000 | +100% | +$9.27M |
|
41
Trip.com Group
TCOM
$48.2B
| $17.8M | 0.43% | 570,000 -30,000 | -5% | -$934K |
|
42
Repare Therapeutics
RPTX
$71.7M
| $17.5M | 0.43% | 570,000 -30,000 | -5% | -$923K |
|
43
Relay Therapeutics
RLAY
$619M
| $17M | 0.41% | +400,000 | New | +$17M |
|
44
Kura Oncology
KURA
$686M
| $16.8M | 0.41% | 549,100 -28,900 | -5% | -$885K |
|
45
Danaher
DHR
$147B
| $16.2M | 0.39% | +75,000 | New | +$16.2M |
|
46
Replimune Group
REPL
$422M
| $16.1M | 0.39% | 700,000 -50,000 | -7% | -$1.15M |
|
47
FibroGen
FGEN
$47.8M
| $15.6M | 0.38% | 380,000 -20,000 | -5% | -$822K |
|
48
BridgeBio Pharma
BBIO
$9.89B
| $15M | 0.36% | 400,000 -200,000 | -33% | -$7.5M |
|
49
Bio-Techne
TECH
$8.5B
| $14.9M | 0.36% | 60,000 -5,000 | -8% | -$1.24M |
|
50
Immunic
IMUX
$80.9M
| $14.9M | 0.36% | 800,000 +200,000 | +33% | +$3.71M |
|